Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Vision Medicals Raises $29 Million to Support Genetic Testing for Infectious Diseases

publication date: Aug 12, 2020

Vision Medicals of Guangzhou raised $29 million in a Series B funding to support its genetic testing services for infectious diseases. The two-year old company completed a $14 million A round last year. Vision has two platforms: pathogen metagenomics (mNGS) diagnosis and CRISPR-Cas12/13 rapid diagnosis technology. In March, Vision's SARS-CoV-2 Clinical Sequencing assay, which uses next-generation sequencing, was approved for use in Europe. The investment was led by CDH Investments and included Cash Capital along with existing investors Volcanics Venture and Zhongjin Qichen. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital